For the Inventor, By the Inventor

Enter assignee name

Bengaluru, India

Aurigene Discovery Technologies Limited

USPTO Granted Patents = 45

% Expired Patents = 31.1

EPO Patents = 14

Forward Citations = 319

Loading Chart...

Loading Chart...

50 inventors (with patents filed for the assignee):

Muralidhara Ramachandra (19 out of 31 patents)

Pottayil Govindan Nair Sasikumar (15 out of 23 patents)

Seetharamaiah Setty Sudarshan Naremaddepalli (12 out of 19 patents)

4. Susanta Samajdar (12 out of 27 patents)

5. Venkateshwar Rao Gummadi (8 out of 15 patents)

6. Subramanya Hosahalli (7 out of 17 patents)

7. Subhendu Mukherjee (5 out of 11 patents)

8. Pottayil Govindan N Sasikumar (5 out of 7 patents)

9. Ramulu Poddutoori (4 out of 13 patents)

10. Sunil Kumar Panigrahi (4 out of 16 patents)

11. Chetan Pandit (3 out of 10 patents)

12. Rajeev Goswami (3 out of 4 patents)

13. Seetharamaiah Setty S Naremaddepalli (3 out of 4 patents)

14. Dinesh Chikkanna (2 out of 5 patents)

15. Srinivasa Raju Sammeta (2 out of 2 patents)

Core Competencies:

IMIDAZOLIDIN-2-ONE

IRAK4 Inhibitors

CDK Inhibitors

1,2,4-Oxadiazole

Thiadiazole Compounds

Hematological Disorders

Peptidomimetic Compounds

Pyridazine Derivatives

PYRAZOLO Compounds

Dual Inhibitors

SMARCA2/4 Degraders

Cyclic Compounds

45 patents: Sort by Forward Citations

1. 12371426 - Pyridazine derivatives as SMARCA2/4 degraders (2025-07-29),

2. 11691987 - Bicyclic heterocyclyl derivatives as IRAK4 inhibitors (2023-07-04),

3. 11680051 - Crystalline forms of 3-substituted 1,2,4-oxadiazole (2023-06-20),

4. 11542275 - Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors (2023-01-03),

5. 11512060 - 1,2,4-oxadiazole derivatives as immunomodulators (2022-11-29),

6. 11497735 - Conjoint therapies for immunomodulation (2022-11-15),

7. 11497734 - Dual inhibitors of TIM-3 and PD-1 pathways (2022-11-15),

8. 11465976 - 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators (2022-10-11),

9. 11419875 - Compounds and compositions for treating hematological disorders (2022-08-23),

10. 11365205 - Imidazolidin-2-one compounds as PRMT5 modulators (2022-06-21),

11. 11311517 - Combination of small molecule CD-47 inhibitors with other anti-cancer agents (2022-04-26),

12. 11274123 - 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling (2022-03-15),

13. 11229636 - Substituted tetrahydroquinolinone compounds as ROR gamma modulators (2022-01-25),

14. 11186576 - Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors (2021-11-30),

15. 11174232 - Substituted heterocyclyl derivatives as CDK inhibitors (2021-11-16),

Company Overview

Aurigene Discovery Technologies Limited, based in Bengaluru, India, specializes in the discovery and development of innovative therapeutics targeting various diseases, particularly hematological disorders. The company focuses on advanced research in areas such as IRAK4 inhibitors, PRMT5 inhibitors, and immunomodulators, contributing to the evolving landscape of cancer treatment. Aurigene's expertise extends to CD47 signaling and CDK inhibitors, positioning it as a key player in the biopharmaceutical sector dedicated to addressing unmet medical needs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

45 Patents

#11 in Bengaluru

#46 in India

#15,436 in the World

Bengaluru, India

Aurigene Discovery Technologies Limited

Forward Citations = 319

50 inventors:

Muralidhara Ramachandra (19 out of 31 patents)

Pottayil Govindan Nair Sasikumar (15 out of 23 patents)

Seetharamaiah Setty Sudarshan Naremaddepalli (12 out of 19 patents)

4. Susanta Samajdar (12 out of 27 patents)

5. Venkateshwar Rao Gummadi (8 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aurigene Discovery Technologies Limited. Retrieved from https://idiyas.com/company/aurigene-discovery-technologies

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…